IL2RB
Interleukin-2 receptor subunit beta
As of the edition of 20 October 2026, IL2RB (interleukin-2 receptor subunit beta, UniProt P14784) has 10 drugs tested at it and 16 companies on the list, 5 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14784
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Immune system; Blood and lymph; Pregnancy and women's health; Infections; Digestive system
- Registered trials of its drugs
- 738
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Aldesleukin | Marketed | Phase 4 | Ended 2005 |
| Denileukin diftitox | Marketed | Phase 4 | Ended 2011 |
| Bempegaldesleukin | Stopped | Phase 3 | none listed |
| Nogapendekin alfa inbakicept | Marketed | Phase 3 | Ends 2036 |
| Pegenzileukin | Active | Phase 2 | none listed |
| Simlukafusp alfa | Active | Phase 3 | none listed |
| BIIB019 | Went quiet | Phase 3 | none listed |
| HUMIK-BETA-1 | Went quiet | Phase 1 | none listed |
| MIK-BETA-1 | Went quiet | Phase 1 | none listed |
| Teceleukin | Marketed | No phase stated | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 8 |
| Total on the list | 16 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Pfizer | Route A |
| Calithera Biosciences | Route A |
The other 13 companies at IL2RB
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at IL2RB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.